Understand Diagnostic Market

Build Diagnostic Plan

Implement Diagnostic Plan

Diagnostic Tracking

Where we've launched new projects

HCV Laboratory Landscape Data in 10 EU Markets
NGS Reporting Assessment in US
Hematology CDx Launch Strategy in China
Lab Education Program for IO Biomarkers in US
PD-L1 Commercialization Planning in US

What's happening in the industry

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor read on...

GenomOncology and med fusion announce the addition of PD-L1 testing and interpretation to the LungSEQ® and 50SEQ® Plus FISH tests for NSCLC read on...

BMS expands focus on precision medicine with investment and planned research collaboration with GRAIL on blood-based cancer screening read on...

Invivoscribe announces long-term collaboration agreement with Illumina and plans release of NGS-based IVD assay kits read on...

Celgene and Agios gain FDA speedy review for AML med enasidenib read on...

Read More News

What you might have missed

PM Buzz NewsDx News Trends June-December 2016
Media MentionDrug Industry Bets Big On Precision Medicine: Five Trends Shaping Care Delivery
Media MentionQ&A: Labceutics' Jordan Clark on Industry, FDA Gap on Rx/Dx Codevelopment Principles
Expert InsightWhite paper: Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product
PublicationThe Evolution of the PD-L1 Testing Market
PublicationImmuno-Oncology Drug Rivalries Highlight Biomarkers’ Opportunities, Challenges
Competitive Benchmarking ReportPharma Readiness for Diagnostic Integration 2017
Competitive Benchmarking ReportWhat are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany

Conferences we're attending


1-5 April 2017
Washington, US

Meet Us

Cologne Conference on Lung Cancer

6-7 April 2017
Cologne, Germany

Meet Us


23-26 April 2017
Orlando, Florida, US

Meet Us